What Spasfon Treats: Main Uses and Benefits

The primary therapeutic role of this medication is in the supportive management of pain associated with muscle spasms across different organ systems. The active substance is generally used when supportive symptom management is appropriate to ease the overall symptom burden. This medication is relevant for easing acute or episodic pain when heightened physiological activity creates noticeable functional strain.

---

Key Therapeutic Areas

The medication is considered relevant for easing painful spasms in therapeutic areas such as the digestive tract (cramping pain and colic), the urogenital system (including pain related to renal and biliary colic), and the gynecological system (including severe menstrual cramps and certain uterine contractions). This approach is used in situations involving certain distressing symptoms, where additional symptomatic support is needed.

“This supportive approach may be part of symptomatic management during acute episodes, contributing to improved day-to-day comfort during periods of heightened symptoms.”

---

Quick Fact: Relief for Spasmodic Pain

---

Easing Specific Symptoms

For the digestive tract, this is used for managing intense, gripping pain. For the urogenital system, it may assist with easing the symptom patterns characteristic of acute or episodic changes. For gynecological discomfort, it may assist with managing the pain caused by painful uterine contractions. The overall benefit supports patients by easing distress and helping to maintain a sense of stability when symptoms are more noticeable.

Regulatory References

1. French High Authority for Health (HAS) Opinion

Official Eligibility Rules for Spasfon

Regulatory documentation defines specific population groups who are eligible or ineligible to use Spasfon (phloroglucinol), based on age, physiological status, and underlying health conditions.

---

Eligibility Domain	Official Regulatory Status
Absolute Contraindications	Use is prohibited for individuals with known hypersensitivity to phloroglucinol or its excipients, as well as for patients with functional ileus or intestinal obstruction [Source 3.5].
Age-Group Rules	The medication is approved for adults and children over 2 years of age [Source 4.1]. Use in children under 2 years is not recommended or efficacy is not established [Source 4.1].
Pregnancy and Lactation	Use during pregnancy is conditional and should only be considered when absolutely necessary or as adjuvant therapy for contractions [Source 3.5]. Use is not recommended for women who are breastfeeding due to a lack of sufficient safety data [Source 3.5].
Comorbidity-Based Restrictions	Oral forms containing excipients like aspartame are contraindicated in patients with phenylketonuria (PKU). Forms containing lactose are contraindicated in patients with conditions like galactose intolerance or Lapp lactase deficiency [Source 4.1].

---

Official labeling establishes clear boundaries: while adults and older children are eligible, the medicine is strictly contraindicated for populations with bowel obstruction, allergies, or specific metabolic disorders tied to the product’s formulation. Use in pregnancy requires clinical necessity, and use during lactation is not recommended.

Interactions with other medicines and products

Officially documented interaction patterns for the active substance Phloroglucinol (Spasfon) are limited, a factor attributed to its pharmacokinetic profile characterized by minimal systemic exposure following oral administration. Regulatory authorities have not identified significant concerns requiring broad warnings concerning common drug–drug interactions, such as those mediated by cytochrome P450 (CYP) enzymes or drug transporters.

Documented Interaction Patterns

Interaction Type	Interacting Substance/Class	Official Regulatory Statement
Pharmacodynamic Interaction	Opioid Analgesics (Narcotic Pain Relievers)	Potential for attenuation (reduction) of the antispasmodic effect.
Pharmacokinetic Interactions	None Documented	No explicit warnings or restrictions are mandated for CYP-mediated or transporter-based interactions.
Contraindicated Combinations	None Documented	No other medicinal products are listed in official regulatory documents as being strictly prohibited for co-administration.

Other Constraints

Timing and Administration: No mandatory timing separation rules are documented in the official prescribing information for co-administered substances, including those concerning food, alcohol, or herbal products.

Exposure-Altering Effects: Regulatory documents do not specify any medicinal products that formally increase or decrease Phloroglucinol's plasma levels to a clinically significant degree requiring a dosage adjustment warning.

How Phloroglucinol Works: Mechanism of Action

Phloroglucinol is classified as a direct spasmolytic agent, characterized by its primary action on smooth muscle tissues found in the digestive, biliary, and urinary systems. The compound interacts directly with the visceral smooth muscle cells, influencing the pathways that regulate involuntary muscle tension and movement. This mechanism operates independently of central and peripheral pain signaling pathways.

1. Direct Modulation of Smooth Muscle Contractility

The influence leads to a reduction in pathway over-activation within the muscle cells, resulting in decreased muscle contractility.

2. Influence on Intracellular Regulatory Cascades

At the molecular level, the spasmolytic effect is associated with the potential inhibition of the enzyme phosphodiesterase (PDE). This modification influences the concentration of the second messengers cyclic nucleotides (cAMP/cGMP). This cascade results in the deactivation of myosin light-chain kinase (MLCK), which is a requisite step for myosin phosphorylation and subsequent smooth muscle contraction.

How Spasfon Is Used: Official Administration Guidelines

Spasfon (Phloroglucinol) is administered through multiple official routes and is primarily used on an intermittent, as-needed basis when a spasm or painful episode occurs. Its usage is defined by specific dosage units and clear limitations on daily intake.

---

Administration Routes and Standard Adult Dosing

Administration Route	Dosage Form	Standard Dose Unit	Maximum Daily Dose (Adults)
Oral	Tablets, Lyophilisates	160 mg (two 80 mg units)	480 mg
Parenteral	Solution for Injection	40 mg	120 mg

Oral administration is intended for outpatient management, while the parenteral (Intramuscular or Intravenous) route is reserved for acute episodes requiring medical supervision. Dosing is repeated only if the painful episode persists, generally observing a minimum interval of 2 hours between doses for the oral form.

---

Form-Specific Use Conditions

The formulation dictates the proper administration technique. The standard film-coated tablets must be swallowed whole with a glass of water. In contrast, the lyophilisate form is designed to dissolve rapidly, allowing it to be taken by dissolving it under the tongue without water. For pediatric use (aged two years and above), the authorized single oral dose is 80 mg, and the dose is to be dissolved in a glass of water, with a maximum of 160 mg per 24 hours.

The injectable solution is administered slowly when given intravenously and should not be mixed with certain other solutions. Overall use is generally defined as short-term for symptomatic relief, with self-treatment using the maximum oral dose restricted to a maximum of 48 hours for acute events.

Research evidence / Overview of studies for Spasfon

---

Evidence for Acute Spasmodic Pain (Urinary and Biliary Tracts)

Research was conducted to evaluate the product in the context of conditions associated with pain in the urinary tract (such as renal colic) and the biliary system (biliary colic). The studies were generally designed as Randomized Controlled Trials (RCTs) and conducted in acute settings, focusing on short-term changes in symptoms. Researchers measured the change in pain intensity. Findings describe patterns related to outcomes monitored in the studies, such as measured pain intensity. The studies examined outcomes in comparison to other active products. However, the use of open-label designs means that certainty remains low about the independent pattern of the medicine compared to an inactive control.

---

Evidence for Digestive Tract Spasms

Research was conducted to evaluate the product in the context of conditions associated with acute pain or episodic manifestations, such as those related to Irritable Bowel Syndrome (IBS). The evidence base includes a limited number of randomized controlled trials. Studies monitored patient-reported outcomes describing perceived discomfort, focusing on the change in abdominal pain intensity and overall changes in IBS symptom severity. Findings varied across studies, and the results were described as being inconsistent in systematic reviews. Systematic reviews reported limited certainty regarding patterns observed in trials comparing the product to an inactive control (placebo).

---

Evidence for Use in Labor and Delivery

Phloroglucinol has also been evaluated in studies focusing on its administration context with other treatments in pregnant women during the peripartum period. The outcomes monitored included measurements of the active phase of labor duration and other cervical parameters. Research describes patterns observed in the studies where the active phase of labor duration was monitored when the product was used alongside standard care. The majority of trials reviewed in meta-analyses were open-label, meaning evidence quality varies across studies.

---

What the Research Landscape Shows: Gaps and Uncertainty

The clinical research is primarily concentrated on acute episodes and short-term symptom patterns. Consequently, there is limited information for long-term outcomes across all indications. Data for certain groups remain insufficient, including research focused on evaluating the product in children or older adults. Key limitations noted include the prevalence of open-label designs and the difficulty in precisely measuring the magnitude of the measured change against placebo for certain acute indications.

Key Studies & References

1. French High Authority for Health (HAS) Transparency Commission Opinion: SPASFON

Official regulatory documents define specific conditions for storing and disposing of Spasfon (Phloroglucinol) to maintain its labeled quality.

Storage Requirements

• Temperature: Store at a temperature not exceeding 30 C and away from excessive heat.
• Protection: The product must be protected from moisture, requiring oral forms to be stored in their original blister packs.
• Handling: The solution for injection requires storage in a dark place to protect it from light.
• Child Safety: Like all medicines, it must be kept out of the sight and reach of children.

Disposal Instructions

Official instructions discourage throwing the medicine away via wastewater (flushing down the toilet or sink). The recommended procedure is to ask a pharmacist how to properly dispose of unused or expired medicine, often through established drug take-back programs.